

Index

Page numbers in **bold** represent tables; those in *italics* represent figures.

- 10/30 rule, 4
- 1-deamino-8-D-arginine vasopressin (DDAVP).
 see desmopressin
- A-ANA. *see* augmented acute normovolemic hemodilution
- acetylstarch, 70
- acute hypervolemic hemodilution (AHH)
 - advantages/disadvantages, 204
 - defined, 200
 - technique, 203–04
- acute normovolemic hemodilution (ANH)
 - advanced use, 207
 - advantages/disadvantages, 206–07
 - allogenic transfusion exposure, 207
 - and coronary artery stenosis, 204
 - defined, 200
 - fractionation, 207
 - history, 200–201
 - indications/eligibility, 204
 - technique of, 204–05
 - troubleshooting, 205–06
- adenosine triphosphate (ATP) generation, 13, 17
- AHH. *see* acute hypervolemic hemodilution (AHH)
- albumin
 - allergic reactions, 72
 - in AOCs, 115–16
 - in coagulation impairment, 71
 - human, 271–72
 - in recombinant blood products, 96–98, 103–04
 - in volume therapy, 71
- albumin-based compounds, 87
- alginate solutions, 71
- allergic reactions, in fluid therapy, 72
- allogenic transfusion. *see also* transfusions
 - defined, 243
 - effects of, 250–55
 - history, 4
 - outcome variables, 250–51
- alloimmunization, 252
- alveolar gas equation, 128
- ϵ -aminocaproic acid (EACA), 81
- ρ -aminomethylbenzoic acid (PAMBA), 81
- anabolic steroids
 - androgen therapy, 30
 - defined, 21
- anaphylactic transfusion reactions, 252
- androgen therapy, 30
- anemia
 - acute vs. chronic, 14
 - adaptive mechanisms
 - cardiac output, 14
 - macrocirculation, 14–15
 - microcirculation, 15–17
 - oxygen extraction, 15
 - oxygen uptake, 15, 16
 - tissue oxygenation, 16
 - vascular tone, 14
 - causes
 - copper deficiency, 40
 - hematinic deficiencies, 45–47
 - inactivity, 162–63
 - iron deficiency, 38–40
 - nutritional deficiencies, 46
 - pressure sores, 163
 - riboflavin deficiency, 44
 - clinical care pathway, **145**
 - defined, 9
 - pathophysiology of, 13–17
 - physiology of, 9–13
 - preoperative treatment, 151
 - primary prevention, 45–46
 - thresholds for, 9
- anemia therapy
 - androgen, 30
 - erythropoiesis-stimulating proteins
 - anabolic steroids, 30
 - EPO, 21–22
 - NESP, 29–30
 - prolactin, 31
 - rHuEPO, 22–29
 - exercise in, 163
 - fluid therapy, 74

- hematinics
 - background, 35–36
 - copper therapy, 40
 - iron therapy, 36–40
- hyperbaric oxygen, 136
- oxygen therapy, 135
- therapy pillars, 18
- anesthesiology, 191
- anesthetic measures
 - controlled hypotension, 193–95
 - drug regimens, 196–97
 - fluid restriction in, 197
 - patient positioning, 192–93
 - patient warming, 195–96
 - PEEP, 196
 - ventilation pattern adjustments, 196
- anesthetist responsibilities, 191–92
- angioneurotic edema, 271
- ANH. *see* acute normovolemic hemodilution (ANH)
- animal farming, 97
- anticoagulation. *see also* coagulation
 - in cell salvage, 219
 - factors
 - antithrombin III, 270
 - α 1-antitrypsine, 271
 - C1-esterase inhibitor, 271
 - human albumin, 271–72
 - immunoglobulins, 272–75
 - α 1-proteinase inhibitor, 271
 - protein C, 270–71
 - protein S, 271
 - history, 3, 4
 - preoperative management, 152
- anti-D-immunoglobulin, 275
- antifibrinolytics
 - aprotinin, 79–80
 - defined, 77
 - EACA, 81
 - PAMBA, 81
 - tranexamic acid, 80–81
- antihemophilia factors (classical). *see also* recombinant clotting factors
 - rFIX, 99
 - rFVIIa, 99–102
 - rFVIII, 98–99
- antisera, 274–75
- antithrombin III, 270
- α 1-antitrypsine, 271
- AOCs. *see* artificial oxygen carriers (AOCs)
- aprotinin, 79–80
- argon beam coagulator, 179
- artificial oxygen carriers (AOCs)
 - in blood management, 119–20
 - defined, 110
 - hemoglobin-based, 111–16
 - history, 110–11
 - perfluorocarbons, 116–19
- artificial platelet substitutes, 120–21
- ATP. *see* adenosine triphosphate (ATP) generation
- augmented acute normovolemic hemodilution (A-ANA), 207. *see also* acute normovolemic hemodilution (ANH)
- autologous blood transfusion
 - defined, 200, 243
 - hemodilution, 203–07
 - history, 200–201
 - platelet-/plasmapheresis, 207–08
 - preoperative donation, 201–03
- autotransfusion, history, 4
- balloon tamponade, 185
- barometric pressure, 127
- Bethesda Units (BUs), 277
- bioethics principles
 - beneficence, 288–89
 - justice, 289
 - respect for persons, 288
- biologic recovery, 267
- biotechnology, 96
- blood banking
 - bank/clinician interaction, 239–40
 - blood donation, 228–30
 - blood safety, 230–34
 - blood separation, 235–39
 - defined, 227
 - history, 227–28
 - maximum blood order schedule, 240
 - transfusion committee, 240
- blood conservation
 - in blood management programs, 300, 304, 308, 316
 - defined, 1
 - in phlebotomy, 162
 - in plan of care, 148
- blood donation
 - donor recruitment, 228–29
 - process, 229–30
 - replacement statistics, 229
- bloodless medicine/surgery, defined, 1
- blood loss. *see also* iatrogenic blood loss
 - adaptive mechanisms, 13–14
 - calculations, 147–48
 - decubital ulcers in, 162
 - tissue adhesive effects, 86

378 Index

- blood management
 - copper therapy, 40
 - current/future practice, 5
 - defined, 1
 - HBOCs, 120–21
 - history, 1–2
 - iron therapy, 36–40
 - military uses, 2–3
 - oxygen therapy, 135–36
 - PFCs in, 119–20
 - plasma fraction(s), 275–79
 - principles/laws in, 287–93
 - recombinant blood products/proteins in, 98–105
 - vitamin therapy, 40–45
- blood management program
 - administration, 5–6
 - coordinator's role, 5–6
 - marketing
 - defined, 299
 - goals/targets, 315
 - nurses' role, 7
 - policies/procedures, 6, 307–08
 - preoperative algorithm, 140
 - reasons/demand for, 5, 299
- blood management program, administration
 - data collection, 316–17
 - priority setting, 315–16
 - routine tasks, 317–18
- blood management program, education
 - content/evaluation, 310
 - defined, 299
 - methods/tools
 - algorithms, 311–12
 - clinical rounds, 311
 - conferences, 311
 - dedicated programs, 313
 - equipment/drug samples, 314
 - lectures/grand rounds, 311
 - one-on-ones, 310–11
 - peer review/audit, 311
 - printed material, 314
 - prospective review, 312
 - reading assignments, 312–13
 - role-plays, 314
 - self-education, 312
 - videotapes, 313–14
 - needs assessment, 309–10
 - participants, 308–09
- blood management program, initiation
 - administrative structure, 306
 - business plan development, 300–304
 - communication facilitation, 306–07
 - education, 308–15
 - hospital administration support, 305
 - initiator education, 300
 - medical structure, 306
 - plan champions, 304–05
 - policies/procedures, 307–08
- blood management program, safety
 - evaluation/benchmarking, 318
 - informed consent errors, **319**
 - safety systems, 318–19
- blood product contents
 - FFP, 247
 - platelets, 246–47
 - red cells, 245–46
- blood safety layers
 - blood screening, 232
 - donor education, 230
 - donor selection/deferral, 231
 - faults in, 233
 - national vigilance systems, 231–32
 - pathogen reduction, 232, **233**
 - postdonation quarantine, 231
- blood separation. *see* whole blood separation
- blood storage
 - bacterial contamination, 234–35
 - irradiation, 235
 - leukocyte reduction/depletion, 235
 - storage condition/time, 234
- blood substitutes
 - and AOCs, 111
 - history, 65–66, 228
 - military uses, 3
- blood volume
 - in AHH, 202–03
 - in ANH, 205
 - calculations, 147–48
 - estimation methods, **147**
 - and fluid therapy, 66
 - and phlebotomy, 161
 - viscosity reduction, 14, 74
- blood washing techniques
 - continuous, 215–16
 - discontinuous/intermittent, 214
 - filtration, 216
- Bohr effect, 16
- bone wax, 87–88
- Boyle's law, 127
- BRAND mnemonic
 - alternatives, 255
 - decision making, 256–58

- “no transfusion/therapy”, 255
- transfusion benefits, 248–50
- transfusion risks, 250–55
- Bunsen solubility coefficient, 10
- BUs. *see* Bethesda Units (BUs)
- C1-esterase inhibitor, 271
- cancer
 - G-CSF/GM-CSF therapy in, 56
 - and growth factors, 57
 - rHuEPO therapy in, 29
 - transfusion risks, 250
 - tumor cells, 221–22
- cardiac output, 14
- caregiver role. *see* iatrogenic blood loss
- cautery, 172
- Cavitron ultrasonic surgical aspirator (CUSA), 180
- cell salvage
 - advantages, 217–18
 - anticoagulation, 219
 - blood quality, 216–17
 - blood washing
 - considerations, 218–19
 - techniques, 214–16
 - cell-saving devices, 212–13
 - contraindications
 - amniotic fluid embolism, 222–23
 - bacterial contamination, 221
 - and concomitant diseases, 223
 - tumor cells, 221–22
 - defined, 211
 - direct/indirect, 212
 - filtration, 219
 - history, 211–12
 - indications for, 223–24
 - methods/devices, 3, 212–13
 - risks/side effects, 219–21
- cell-saving devices, 3, 212–13. *see also* cell salvage
- Charles’ law, 127
- charters/bills/laws
 - advance directive, 291
 - informed consent, 290–91
 - international examples, 289–90
 - minors, 291–92
 - pregnancy/motherhood, 291
- clinical trials
 - and compassionate use, 287
 - HBOCs, 115
 - hemostatic drugs, 85
 - increased FiO₂, 205
 - interoperative plateletpheresis, 201
 - platelet growth factors, 59
 - protein C, 271
 - recombinant factor concentrates, 96–97
 - rFVIIa, 100
- coagulation. *see also* anticoagulation
 - coaptive, 172
 - electrocoagulation, 172
 - factor mixes
 - cryoprecipitate, 268
 - prothrombin complex concentrate, 268
 - microwave, 177–78
 - obliterative, 172
 - single factor concentrates
 - factor IX, 269
 - factor VII, 270
 - factor VIII, 269
 - factor XI, 270
 - factor XIII, 269–70
 - fibrinogen, 269
 - prothrombin, 270
 - thrombin, 270
 - von Willebrand, 269
 - surgical, 172
 - in volume therapy, 71–72
- coagulopathies
 - pharmacological, 153
 - preoperative treatment, 151–52
 - tests for, **146**
- cobalamins, 42–43
- Cohn’s fractionation, 3
- collagen, 88
- colloid(s)
 - defined, 65
 - history, 65
 - solutions
 - acetylstarch, 70
 - albumin, 71
 - alginates, 71
 - dextran, 70
 - gelatins, 70–71
 - HES, 69–70
- colony-stimulating factors, defined, 50
- compassionate use
 - defined, 287
 - FDA protocol, **296**
- compression
 - balloon tamponade, 185
 - bandaging, 184
 - manual wound, 183–84
 - mesh wrap, 184–85
 - packing, 184

380 Index

- conjugated estrogens
 defined, 77
 as hemostatic drug, 84
- controlled hypotension
 concept of, 193–95
 fluid restriction in, 193–94
 induction agents, **194**
 regional/epidural anesthesia in, 194
 vasodilatation drugs in, 194
- copper deficiency/therapy, 40
- coronary artery stenosis, 204
- Coumadin overdose, and FFP, **249**
- cryoprecipitate, 268
 and FFP, 268
 and fibrinogen, 269
 in hemophilia therapy, 276
 in plasma fraction reduction, 279
 in von Willebrand disease, 277
- cryopreservation, in PAD, 202
- crystalloid(s), 71
 defined, 65
 solutions
 brand names, 67
 classifications of, 67
 glucose, 67–68
 hypertonic fluids, 68–69
 sodium chloride 0.9%, 67
- CUSA, Cavitron ultrasonic surgical aspirator (CUSA)
- cutting devices. *see* surgical tools
- cyanoacrylates, 88
- cytokines
 in adjuvant therapies, 26
 defined, 50
 in erythropoiesis impairment, 28, 29
 in erythropoietin hyporesponsiveness, 25
 IL-11, 53–54
- Dalton's law, 127
- darbepoetin. *see* novel erythropoiesis-stimulating protein (NESP)
- DDAVP. *see* desmopressin
- decubital ulcers, 162
- desiccation, defined, 172
- desmopressin, 81–82
- dextran
 in fluid therapy, 70
 side effects, 71–72
- diathermy, 172
- drains, use of, 185
- ϵ -aminocaproic acid (EACA), 81
- ECCs. *see* extracorporeal circuits (ECCs)
- electrical current, for surgery, 175–77
- electrocautery
 defined, 172
 tool, 176
- electrocoagulation, 172
- electrosurgery, 176–77
- electrothermal bipolar vessel sealing, 177
- EPO. *see* erythropoietin (EPO)
- eptacog, 99–102
- erythropoiesis
 EPO in, 22
 hematinics in, 35–36
 physiology of, 35
 rHuEPO, 28
 steps in, 22
- erythropoiesis-stimulating proteins
 anabolic steroids, 30
 EPO, 21–22
 NESP, 29–30
 prolactin, 31
 rHuEPO, 22–29
- erythropoietin (EPO). *see also* recombinant human erythropoietin (rHuEPO)
 biological role, 24–25
 defined, 21
 EPO receptor, 22
 in erythropoiesis (normal), 21–22
 history, 21
 levels, 22
 structure diagram, 30
- erythropoietin hyporesponsiveness
 aluminum metabolism, 25
 causes, 25–26
 diagrammed, 27
 drug interference, 26
 erythropoiesis levels, 25
 hematinic deficiencies, 25–26
 hyperparathyroidism, 25
 infection/inflammation, 25
 iron overload, 25
 rHuEPO therapy in, 25
- erythropoietin resistance. *see* erythropoietin hyporesponsiveness
- estrogens, conjugated, 77, 84
- ethics, 287. *see also* bioethics principles; charters/bills/laws
- exercise, in anemia therapy, 163
- extracorporeal circuits (ECCs), 165–68
- Farhaeus effect, 11
- FCD. *see* functional capillary density (FCD)
- febrile nonhemolytic transfusion reaction (FNHTR), 250–51, 252
- FFP. *see* fresh-frozen plasma (FFP)
 regional vs. general anesthesia, 197
- fibrinogen, 269

- fibrinolysis
 - in blood management, 78–79
 - physiology of, 78
- fibrin sealants, 87
- Fick's law of diffusion, 10, 11
- FiO₂. *see* inspiratory oxygen fraction (FiO₂)
- fluid administration, in anesthetic measures, 197
- fluid therapy
 - in anemia (severe), 74
 - in blood management, 73–74
 - colloid solutions, 69–71
 - crystalloid solutions, 67–69
 - fluid choice, 73
 - history, 65–66
 - hypertonic fluids, 68–69
 - hypovolemia/hypervolemia, 73
 - intravenous fluids, 67
 - monitoring tools, 73
 - need for, 65, 66–67
 - polydisperse solutions, 69, 70
 - resuscitation timing, 72–73
 - solution effects, 73
 - vs. transfusion, 66–67
 - volume household, 67
- FNHTR. *see* febrile nonhemolytic transfusion reaction (FNHTR)
- folates, 43–44
- fresh-frozen plasma (FFP)
 - in blood product contents, 247
 - in hemophilia therapy, 276
 - side effects, 71–72
 - in whole blood separation, 237
- functional capillary density (FCD), 11

- G-CSF. *see* granulocyte colony stimulating factor (G-CSF)
- gelatin
 - solutions, 70–71
 - as tissue adhesive/sealant, 88
- glucose solutions, 67–68
- granulocyte colony stimulating factor (G-CSF)
 - recombinant forms, 54–56
 - synthesis of, 54
- granulocyte macrophage colony stimulating factor (GM-CSF)
 - clinical use, 56–57
 - recombinant forms, 56
- growth factors
 - in blood management, 57–61
 - concerns about, 57
 - for hematopoiesis
 - leukopoiesis, 52
 - megakaryopoiesis, 50–51, 55
 - for leukocytes
 - G-CSF, 53–56
 - GM-CSF, 56–57
 - in multilineal hematological failure management, 60–61
 - in neutropenia management, 60
 - for platelets
 - cytokine combinations, 54
 - IL-11, 53–54
 - rhuTOP, 53
 - thrombopoietin, 52–53
 - pluripotency of, 57, 58
 - in thrombocytopenia management, 57–60

- Haldane effect, 10
- Halstedian principles
 - history, 3
 - tenets, 174
- HBOCs. *see* hemoglobin-based oxygen carriers (HBOCs)
- heat, in surgery, 175
- hematinic deficiencies
 - anemia therapy in, 46–47
 - iatrogenically induced, 46
- hematinics. *see also* iron therapy; vitamin therapy
 - adjunctive therapy, 47
 - and allogeneic transfusion, 45–46
 - anemia prevention/therapy, 45–46
 - in blood management, 45–47
 - copper therapy, 40
 - defined, 35
 - in erythropoiesis, 35–36
 - in hemoglobin synthesis, 35–36
 - interactions of, 45
- hematocrit reduction, 11
- hematopoiesis
 - and copper deficiency, 40
 - diagrammed, 51
 - EPO targets in, 22
 - growth factors, 50–52
 - and vitamins, 40, 45–46
- hematopoietic cell growth factors, 50
- hemihepatic vascular clamping, 182
- hemodilution
 - AHH, 203–04
 - ANH, 204–07
 - and coronary artery stenosis, 204
 - defined, 200
- hemoglobin
 - oxygen affinity factors, 12
 - in oxygen delivery, 13
 - relaxed/tense forms, 12
 - synthesis, 35–36
 - types (human), 36

382 Index

- hemoglobin-based oxygen carriers (HBOCs)
 - in acute normovolemic hemodilution, 120
 - defined, 110
 - effects of, 112–15
 - in hemorrhagic shock, 120
 - new products, 115–16
 - potential indications, 115
 - properties of, 116–17
 - vs. red cell usage, 120
 - in sickle cell anemia, 120
 - sources of, 111
 - in surgical blood loss, 120
 - in trauma, 120
- hemoglobin solution effects
 - on erythropoiesis, 114
 - hemostaseological alterations, 114
 - on immune system, 114
 - infectious risks, 114
 - intravascular half-life, 114
 - oncotic effects, 113
 - oxidative damage, 114
 - oxygen affinity, 113
 - on renal system, 114
 - rheological properties, 113
 - shelf life, 114
 - vasopressor effects, 113–14
 - viscosity, 113
- hemolytic transfusion reactions, 253
- hemophilia
 - antihemophilia factors, 98–105
 - and desmopressin, 82
 - plasma fraction(s) in, 276
 - and recombinant blood products, 96
- hemorrhage treatment. *see also* hemostasis
 - blood management, 3
 - coagulation factors, 268
 - FFP, 260
 - platelet transfusions, 259
- hemorrhagic disease
 - in newborns, 83, 260
- hemostasis
 - achievement methods
 - compression, 183–85
 - drains, 185
 - patient positioning, 186
 - vessel occlusion, 181–83
 - hemostatic drugs
 - antifibrinolytics, 78–81
 - in clinical trials, 85
 - conjugated estrogens, 84
 - desmopressin, 81–82
 - drug recommendations, 85
 - hormones, 84
 - vitamin K-group, 83–84
 - history, 77–78
 - local agents, 86–90
 - physical/chemical measures, 89
 - tissue adhesive/sealant(s)
 - albumin-based compounds, 87
 - bone wax, 87–88
 - collagen, 88
 - cyanoacrylates, 88
 - fibrin sealants, 87
 - gelatin, 88
 - hydrogels, 88
 - microporous polysaccharide hemosphere, 88–89
 - oxidized cellulose, 88
 - uses/application of, 89
 - topical agents, 90
 - vasoconstrictors, 89–90
- hemostatic drugs
 - antifibrinolytics, 78–81
 - in clinical trials, 85
 - conjugated estrogens, 84
 - desmopressin, 81–82
 - drug recommendations, 85
 - hormones, 84
 - vitamin K-group, 83–84
 - hemostatics, defined, 77
 - hemovigilance, defined, 227
 - Henry-Dalton equation, 10
 - Henry's law, 127
 - hepatic vascular exclusion, selective, 182
 - hepcidin
 - in iron metabolism, 37–38
 - regulation of, 38
 - HES. *see* hydroxyethyl starch (HES)
 - heterologous transfusion, defined, 243
 - hormones
 - defined, 50
 - as hemostatic drugs, 84
 - hot-jet coagulator, 175
 - Hufner's number, 9
 - hydrogels, 88
 - hydroxyethyl starch (HES)
 - classifications of, 70
 - history, 66
 - pharmacology of, 69–70
 - side effects, 70, 72
 - substitution degree, 69
 - hyperbaric oxygen therapy
 - in anemia (severe), 136
 - chambers for, 133
 - contraindications, 133

- defined, 125
- indications, 132–33
- recommendation measures, 134–35
- in sickle cell crisis, 136
- treatment patterns, 133–34
- hyperchloremic metabolic acidosis, 72
- hyperimmune immunoglobulins of human origin, 274
- hypertonic fluids, 68–69
- hypovolemia/normovolemia, 13–14
- hypoxia
 - and EPO, 22
 - and tissue oxygenation, 16–17
- iatrogenic blood loss
 - in blood management, 168
 - causes
 - diagnostic interventions, 164
 - ECCs, 165–66
 - elapsed time, 167–68
 - inactivity/bed rest, 162–63
 - medications, 164–65
 - phlebotomy, 160–62
 - stress, 163–64
 - defined, 160
 - drug effects on, 165
 - reduction strategies
 - ambulation/exercise, 163
 - medication choice, 164–65
 - phlebotomy amount/volumes, 162–63
 - ulcer prophylaxis, 163–64
 - vascular access skill/methods, 164
- IL-11. *see* interleukin 11 (IL-11)
- immunoglobulin monomer, 272
- immunoglobulins
 - anti-D-immunoglobulin, 275
 - antisera, 274–75
 - IVIG, 273–74
- immunological reactions
 - alloimmunization, 252
 - to anaphylactic transfusions, 252
 - FNHTR, 252
 - to hemolytic transfusions, 253
 - microchimerism, 253–54
 - post-transfusion purpura, 254
 - TA-GvHD, 253
 - transfusion-related acute lung injury, 253
- IND. *see* investigational new drug (IND)
- infrared contact coagulator, 178
- inhalation oxygen therapy, 125. *see also* normobaric oxygen
 - inhalation therapy
- inspiratory oxygen fraction (FiO₂)
 - in hyperbaric conditions, 129
 - in normobaric conditions, 132
 - physiology, 10, 127
- interleukin 11 (IL-11), 53–54. *see also* recombinant human
 - interleukin 11 (rhIL-11)
- interleukins, defined, 50
- international unit (IU), 267
- intravascular recovery, 267
- intravenous immunoglobulins of human origin (IVIG),
 - 273–74
- investigational new drug (IND)
 - compassionate use of, 296
 - defined, 287
- iron
 - absorption, 38
 - deficiency
 - absolute/relative/functional, 38
 - differential diagnosis, 42
 - markers of, 39
 - defined, 35
 - metabolism, 37–38
 - physiology, 36–38
 - therapeutic use, 38–39
 - therapy
 - essays for, 41–42
 - intravenous preparations, 39
 - oral preparations, 38–39
 - parenteral iron formulas, 40
 - physiology, 36–38
 - side effects, 38–39
 - uses of, 38–39
- IU. *see* international unit (IU)
- IVIG. *see* intravenous immunoglobulins of human origin (IVIG)
- Jehovah's Witnesses
 - blood acceptance attitudes, 295
 - and bloodless medicine, 1–2
 - hospital liaison committees, 2
 - medical care attitudes, 293
 - physician care of, 2, 293–95
 - support for patients/physicians, 295–96
- kidney function, and fluid therapy, 72
- kinetic energy, in surgery, 179–80
- laser surgery, 178–79
- L-Carnitine, 44–45
- leukopoiesis, 52
- lightning
 - argon beam coagulation, 179
 - and plasma scalpel, 179

384 Index

- light, surgical
 infrared contact coagulator, 178
 laser, 178–79
- local hemostatic agents, 86–90
- lysine derivatives
 EACA, 81
 PAMBA, 81
 tranexamic acid, 80–81
- macrocirculation. *see* oxygen delivery/transport
- Makuuchi's maneuver, 182
- malignancy. *see* cancer
- MANAGER mnemonic, 279–81
- manual wound compression, 183–84
- megakaryopoiesis, 50–51, 55
- megapoietin. *see* thrombopoietin
- mesh wrap, 184–85
- microchimerism, 253–54
- microcirculation. *see* oxygen uptake; tissue oxygenation
- microporous polysaccharide hemisphere, 88–89
- microvasculature
 and HBOCs, 113
 HES solution effects, 70
 oxygen delivery to, 11–12, 15–16
 and viscosity increases, 74
- microwave coagulation, 177–78
- military uses
 blood management, 2–3
 blood substitutes, 3, 111
 transfusion medicine, 3
- mineral zeolite, 89
- minors, decision making of, 291–92
- mitochondria, oxygen utilization factors, 13
- modified hemoglobin solutions, 112
- multilineal hematological failure management, 60–61
- myoglobin-facilitated oxygen diffusion, 13
- NESP. *see* novel erythropoiesis-stimulating protein (NESP)
- neutropenia
 and copper deficiency, 40
 G-CSF/GM-CSF therapy in, 56
 granulocyte transfusions in, 260
 and growth factors, 57
 management of, 60
- normal saline, 67
- normobaric oxygen inhalation therapy
 diagnostic measures, 130
 indications, 130
 oxygen delivery systems, 131–32
 oxygen mixing, 131
 oxygen supply, 130–31
 recommendations for, 132
- novel erythropoiesis-stimulating protein (NESP)
 defined, 21
 effects, 30
- obliterative coagulation, 172
- octocog, 98–99
- oprelvekin. *see* interleukin 11 (IL-11)
- organized programs. *see* blood management program
 terms
- orphan drug, defined, 265
- oxidized cellulose, 88
- oxygen
 consumption, 13
 delivery/consumption relationship, 17
 dissociation curve, 12
 extraction, 15
 extraction ratio, 13
 gas laws, 127–28
 hyperbaric conditions, 129–30
 physics/physiology of, 127–28
- oxygen delivery/transport. *see also* oxygen uptake
 Bunsen solubility coefficient, 10
 equation, 9, 17
 FiO_2 , 10
 flow, 9
 hemoglobin, 9–10, 13
 Henry-Dalton equation, 10
 to microvasculature, 11
 by perfluorocarbons, 118–19
- oxygen therapy
 in anemia/hemorrhagic shock, 135
 in blood management, 135–36
 defined, 125
 drug interactions, 129
 effects on human body
 cerebral, 128
 circulatory, 128
 immunological, 128
 metabolic, 128
 ocular, 128
 oxygen toxicity, 129
 of pressurized oxygen, 129–30
 pulmonary, 129
 history, 125–27
 hyperbaric oxygen treatment, 125, 132–35
 hyperoxic ventilation, 135
 normobaric oxygen inhalation, 130–32
- oxygen uptake
 in anemia, 15
 carbon dioxide release, 10
 Fick's law of diffusion, 10, 11
 Haldane effect, 10

- pulmonary gas exchange, 10, 15
 - by red cells, 10–12
 - by tissues, 12–13, 16–17
 - packing, 184
 - PAD. *see* preoperative autologous donation (PAD)
 - ρ -aminomethylbenzoic acid (PAMBA), 81
 - patient
 - history
 - anemia symptoms, 141
 - bleeding disorders, 141–42
 - body systems review, 142–43
 - chief complaint, 141–42
 - demographics, 141
 - drug/supplement list, 143
 - food/drug allergies, 143
 - hemostasis, obstacles to, 142
 - overview, 139–40
 - screening questionnaire, 142
 - positioning
 - in anesthetic measures, 192–93
 - for hemostasis, 186
 - rights, 287
 - PCC. *see* prothrombin complex concentrates (PCC)
 - PEEP. *see* positive end-expiratory pressure (PEEP)
 - pegylated recombinant human megakaryocyte growth and development factor (PED-rhuMGDF), 53
 - perfluorocarbons (PFCs), 119–20
 - A-ANA, 120–21
 - in anemia (severe), 119
 - in blood management, 119–20
 - characteristics of, 116–18
 - defined, 110
 - history, 111
 - oxygen delivery by, 118–19
 - in sickle cell anemia, 120
 - tested/potential indications, 119
 - PFCs. *see* perfluorocarbons (PFCs)
 - pharming, 97
 - phlebotomy-induced blood loss
 - “bloodless” monitoring, 162
 - education/policies, 162
 - and laboratory tests, 160
 - reduction of, 161–62
 - physicians. *see also* iatrogenic blood loss
 - bloodless treatment development, 2
 - conscience of, 292–93
 - and Jehovah’s Witnesses, 2
 - transfusion decision making, 244–45
 - plan of care
 - computer-based planning, 149
 - emergency planning, 149
 - example plan, 149–51
 - problem list, 148
 - therapeutic options, 149
 - treatment/therapy goals, 148
 - plasma
 - anatomy of, 266
 - substitutes, defined, 65
 - plasma-derived blood proteins, 106
 - plasma fractionation
 - chromatography, 238–39
 - precipitation, 238
 - production methods, 239
 - plasma fraction(s)
 - anticoagulation factors, 270–75
 - antithrombin III, 270
 - C1-esterase inhibitor, 271
 - human albumin, 271–72
 - immunoglobulins, 272–75
 - protein C, 270–71
 - protein S, 271
 - blood management
 - in congenital clotting factor deficiencies, 278
 - general, 275–76
 - in hemophilia, 276
 - inhibitor treatment, 276–77
 - in liver-related coagulopathies, 278
 - in vitamin K deficiency, 278
 - in von Willebrand disease, 277
 - coagulation factors
 - cryoprecipitate, 268
 - factor IX concentrates, 269
 - factors XIII, 269–70
 - factor VII, 270
 - factor VIII concentrate, 269
 - factor XI, 270
 - fibrinogen, 269
 - prothrombin, 270
 - prothrombin complex concentrate, 268
 - thrombin, 270
 - von Willebrand factor concentrates, 269
 - concept of, 266–68
 - defined, 265
 - in disseminated intravascular coagulation, 278–79
 - history, 265–66
 - in other blood product reduction, 279
 - use reduction, 279–81
- plasma-/platelet-sequestration, 200
- plasma scalpel, 179
- platelet-/plasmapheresis
 - advantages/disadvantages, 208
 - techniques, 207

386 Index

- platelet(s)
 disorders, 82
 growth factors, 52–54
 maturation process, 51
 and megakaryocytes, 50–52
 substitutes, 120–21
 synthesis, 52
- plus-minus-implications (PMI), in transfusion decision, 256
- polycythemia, 151
- polydisperse solutions, 69, 70
- positive end-expiratory pressure (PEEP), 196
- potency, in plasma fractionation, 265, 267
- preoperative algorithm, 140
- preoperative autologous donation (PAD)
 advantages/disadvantages, 202–03
 blood collection/storage, 202
 costs of, 203
 cryopreservation, 202
 defined, 200
 eligibility for, 201
 erythropoiesis stimulation, 202–03
 predonation iron therapy, 202
 in pregnancy, 203
 program administration, 201–02
 retransfusion issues, 202
 side effects, 203
- pressure sores, in blood loss, 162–63
- pressurized oxygen, effects of, 129–30
- principles/laws
 bioethics, 288–89
 charters/bills/laws, 289–92
 in decision making, 287
 human/patients' rights, 289
 pyramid of principles, 288
- Pringle maneuver, 181
- program, defined, 299
- prolactin, 31
- α 1-proteinase inhibitor, 271
- protein C, 270–71
- protein S, 271
- prothrombin, 270
- prothrombin complex concentrates (PCC), 268
- pulmonary gas exchange, 10, 15
- purity, of plasma, 267
- purpura, post-transfusion, 254
- recombinant blood products/proteins
 history, 96
 vs. plasma-derived blood proteins, 106
 production of, 97–98
 safety, 98
 vaccines/sera/immunoglobulins, 105
- recombinant clotting factors. *see also* antihemophilia factors
 (classical)
 fibrinogen, 103
 rFXIII, 103
 rhAT, 103
 rHb, 104–05
 rHSA, 103–04
 thrombin, 103
- recombinant drugs, defined, 96
- recombinant factor IX (rFIX), 99
- recombinant factor VIIa (rFVIIa)
 dose regimen, 102
 off-label uses, 101
 vs. other recombinant factors, 99
 recommended uses, 100–102
 as “universal” hemostatic agent, 99
- recombinant factor VIII (rFVIII), 98–99
- recombinant factor XIII (rFXIII), 103
- recombinant hemoglobins (rHb), 104–05
- recombinant human antithrombin (rhAT), 103
- recombinant human erythropoietin (rHuEPO)
 adjuvant therapies, 26
 application, 23
 benefits, 26–29
 defined, 21
 dosage/response, 23, 24
 as a drug, 22–26
 history, 21
 metabolization, 23
 replacement methods (future), 29
 side effects, 23–24
 supplements to, 26
 synthetic production, 23
 and transfusions, 29
- recombinant human interleukin 11 (rhuIL-11), 53–54
- recombinant human prolactin, 31
- recombinant human serum albumin (rHSA), 103–04
- recombinant human thrombopoietin (rhuTPO), 53
- red cells
 in microcirculation
 pathophysiology, 13–17
 regular physiology, 9–13
 oxygen release, 12–13, 16
 oxygen uptake, 10, 15
 tissue oxygenation, 11, 15
- replacement fluids, colloid solutions as, 67
- rFVIIa. *see* recombinant factor VIIa (rFVIIa)
- rFVIII. *see* recombinant factor VIII (rFVIII)
- rFIX. *see* recombinant factor IX (rFIX)
- rFXIII. *see* recombinant factor XIII (rFXIII)
- rhAT. *see* recombinant human antithrombin (rhAT)
- rHb. *see* recombinant hemoglobins (rHb)

- rHSA. *see* recombinant human serum albumin (rHSA)
- rHuEPO. *see* recombinant human erythropoietin (rHuEPO)
- rhuTPO. *see* recombinant human thrombopoietin (rhuTPO)
- riboflavin, 44
- rouleaux formations, 11
- safety. *see* blood management program, safety
- saline-enhanced thermal sealing, 177
- scalpels
 - hemostatic, 176
 - plain, 175
 - plasma, 179
 - ultrasonic/harmonic, 180
- Seldinger's technique, 164
- sodium chloride 0.9% (normal saline), 67
- specific activity
 - described, 267
 - in factor VIII concentrate, 269
- stress ulcers, in blood loss, 163
- substitution degree
 - of HES, 69
- surgery preparation
 - calculations
 - blood loss, allowable, 148
 - blood loss, expected, 147
 - blood/red cell volume, 147–48
 - minimum hemoglobin/hematocrit, 148
 - clinical care pathway, **145**
 - equipment preparation, 154, **156**
 - laboratory tests, 144–46
 - patient history
 - anemia symptoms, 141
 - bleeding disorders, 141–42
 - body systems review, 142–43
 - chief complaint, 141–42
 - demographics, 141
 - drug/supplement list, 143
 - food/drug allergies, 143
 - hemostasis, obstacles to, 142
 - overview, 139–40
 - screening questionnaire, **142**
 - patient preparation
 - adverse condition treatment, 151–54
 - education, 154
 - surgical field optimization, 154
 - physical examination, 143–44
 - plan of care
 - computer-based planning, 149
 - emergency planning, 149
 - example plan, 149–51
 - problem list, 148
 - therapeutic options, 149
 - treatment/therapy goals, 148
- preoperative workups
 - of accompanying disorders, 145–46
 - of anemia, 144
 - of impaired clotting, 144–45
- surgical coagulation, 172
- surgical cutting
 - blood loss impact, 180
 - device comparison, **181**
 - vibration in, 180
- surgical techniques
 - Halstedian principles, 174
 - heat, 175
 - history, 172–74
 - and patient outcomes, 174
 - surgeon selection, 174
 - technique selection, 174
 - tools, 175
- surgical tools
 - argon beam coagulator, 179
 - electrical current, 175–77
 - electrocautery, 176
 - electrosurgery, 176–77
 - heat, 175
 - ideal characteristics, 175
 - kinetic energy, 179–80
 - light, 178–79
 - microwaves, 177–78
 - scalpels
 - hemostatic, 176
 - plain, 175
 - plasma, 179
 - ultrasonic/harmonic, 180
 - thermocoagulator, 175
- survival study, described, 267
- sympathetic nerve stimulation, 14
- TACO. *see* transfusion-associated circulatory overload (TACO)
- TA-GvHD. *see* transfusion-associated graft-versus-host disease (TA-GvHD)
- thermal knife, 172
- thermocoagulator, 175
- thrombin, 270
- thrombocytopenia
 - management of, 57–60
 - treatment measures, **59**
- thrombocytopenic bleeding, 82
- thrombopoietin. *see also* recombinant human thrombopoietin (rhuTPO)
 - PEG-rhuMGDF in, 53
 - in platelet synthesis, 52

388 Index

- through level, in coagulation factors, 267
- tissue adhesive/sealant(s)
- albumin-based compounds, 87
 - bone wax, 87–88
 - collagen, 88
 - cyanoacrylates, 88
 - defined, 77
 - fibrin sealants, 87
 - gelatin, 88
 - hydrogels, 88
 - microporous polysaccharide hemisphere, 88–89
 - mineral zeolite, 89
 - oxidized cellulose, 88
 - use of, 89
- tissue glue. *see* tissue adhesive/sealant(s)
- tissue oxygenation
- ANH in, 206–07
 - and fluid therapy, 73–74
 - and hemodilution, 16
 - PFCs in, 119
 - physiology, 11–13
 - and transfusion decision, 247–50
- total vascular exclusion, 181
- TRALI. *see* transfusion-related acute lung injury (TRALI)
- tranexamic acid, 80–81
- transferrin, 27
- in erythropoietin hyporesponsiveness, 25
 - essays for iron therapy, 41
 - and hepcidin regulation, 38
 - in iron deficiency, 42
 - in iron physiology, 36–37
 - saturation, 39
- transfusion-associated circulatory overload (TACO), 254
- transfusion-associated graft-versus-host disease (TA-GvHD), 253
- transfusion-free medicine/surgery, defined, 1
- transfusion medicine
- history, 4
 - military development of, 3
- transfusion-related acute lung injury (TRALI), 253
- transfusion-related immunomodulation (TRIM), 250
- transfusions. *see also* BRAND mnemonic
- alternatives, 4, 255
 - benefits, 248–50
 - blood product contents, 245–47
 - decision making
 - biases, 257–58
 - grid analysis, 256–57
 - options, 256
 - by physicians, 244–45
 - PMI, 256
 - tools, 245, 256–58
 - defined, 243
 - guidelines
 - FFP, 260
 - granulocytes, 259–60
 - leukoreduction in, 260
 - platelets, 259
 - red cells, 258–59
 - and hematinic therapy, 46–47
 - history, 243–44
 - microcirculation effects, 250–51
 - and rHuEPO, 29
 - risks/side effects
 - allogenic transfusion effects, 250–55
 - bacterial contamination, 252
 - circulatory effects, 254
 - clerical error, 252
 - immunological reactions, 252–54
 - immunomodulatory effects, 254–55
 - iron overload, 254
 - outcome variables, 250–51
 - specialists, 4
 - “triggers”, 244–45, 247–48
 - and volume replacement, 73
- transfusion-transmittable infections (TTIs), 251–52
- TRIM. *see* transfusion-related immunomodulation (TRIM)
- TTIs. *see* transfusion-transmittable infections (TTIs)
- ultrasonic/harmonic scalpel, 180
- vaccines/sera/immunoglobulins, 105
- vascular tone, 14
- ventilation pattern choices, 196
- vessel occlusion methods
- embolization, 182
 - endovascular grafts, 182
 - sutures/clips, 181
 - tourniquet, 182
 - vascular maneuvers
 - hemihepatic vascular clamping, 182
 - hepatic vascular exclusion, selective, 182
 - Makuuchi’s maneuver, 182
 - Pringle maneuver, 181
 - total vascular exclusion, 181
- vitamin therapy
- cobalamins (vitamin B₁₂), 42–43
 - folates, 43–44
 - L-Carnitine, 44–45
 - riboflavin, 44
 - role of, 40–42
 - vitamin A, 45

- vitamin-B group, 45
- vitamin C, 44
- vitamin E, 45
- vitamin K, 45, 78, 83–84
- volume therapy
 - defined, 65
 - side effects
 - coagulation, 71–72
 - hyperchloremic metabolic acidosis, 72
 - kidney function, 72
- von Willebrand disease
 - and conjugated estrogens, 84
 - and desmopressin, 82
- von Willebrand factor concentrates, 269
- warming, of patients, 195–96
- white cells, maturation process, 51
- whole blood separation
 - additives, 236
 - FFP, 237
 - granulocytes, 237
 - plasma fractionation, 238–39
 - platelet concentrates, 236–37
 - process, 235–36
 - red cell concentrates, 236
- window period, defined, 227

